SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Thomassen L)
 

Search: WFRF:(Thomassen L) > (2005-2009) > Nordic collaborativ...

  • Karppinen, S. -M. (author)

Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies

  • Article/chapterEnglish2006

Publisher, publication year, extent ...

  • BMJ,2006

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:14637813-bd56-47a5-8610-60ad65b0803e
  • https://lup.lub.lu.se/record/378323URI
  • https://doi.org/10.1136/jmg.2006.041731DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:112436992URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background: BARD1 was originally identified as a BRCA1- interacting protein but has also been described in tumour-suppressive functions independent of BRCA1. Several studies have indicated that the BARD1 gene is a potential target for germline changes predisposing to breast and ovarian cancer. The C- terminal Cys557Ser change has previously been uncovered to associate with an increased risk of breast cancer and was recently shown to result in defective apoptotic activities. Aim and methods: Conformation- sensitive gel electrophoresis, minisequencing, TaqMan assays, denaturing high- performance liquid chromatography analysis and DNA sequencing were used to investigate the prevalence of the Cys557Ser allele in a large Nordic case - control study cohort consisting of 2906 patients with breast or ovarian cancer, 734 with prostate cancer, 188 with colorectal cancer, 128 men with breast cancer, and 3591 controls from Finland, Iceland, Denmark, Sweden and Norway. Results: The frequency of the BARD1 Cys557Ser variant seemed to increase among patients from families with breast or ovarian cancer lacking BRCA1 or BRCA2 mutations: a significant difference was obtained compared with controls ( 6.8% v 2.7%; p < 0.001; odds ratio ( OR) 2.6; 95% confidence interval (CI) 1.7 to 4.0) and with patients from BRCA1/ BRCA2 mutation- positive families ( 6.8% v 2.2%; p = 0.01; OR 3.2; 95% CI 1.2 to 8.3). In contrast, no major association with male breast, ovarian, colorectal or prostate cancer was observed. Additionally, a novel BARD1 allele resulting in Ser558Pro was identified in familial breast cancer cases. Conclusion: These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Barkardottir, R. B. (author)
  • Harbst, KatjaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-kbn (author)
  • Sydenham, T. (author)
  • Syrjakoski, K. (author)
  • Schleutker, J. (author)
  • Ikonen, T. (author)
  • Pylkas, K. (author)
  • Rapakko, K. (author)
  • Erkko, H. (author)
  • Johannesdottir, G. (author)
  • Gerdes, A. -M. (author)
  • Thomassen, M. (author)
  • Agnarsson, B. A. (author)
  • Grip, M. (author)
  • Kallioniemi, A. (author)
  • Kere, J.Karolinska Institutet (author)
  • Aaltonen, L. A. (author)
  • Arason, A. (author)
  • Moller, P. (author)
  • Kruse, T. A. (author)
  • Borg, ÅkeLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-abo (author)
  • Winqvist, R. (author)
  • Backenhorn, K (author)
  • Bröstcancer-genetikSektion I (creator_code:org_t)

Related titles

  • In:Journal of Medical Genetics: BMJ43:11, s. 856-8620022-25931468-6244

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view